Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Halozyme Therapeutics, a biopharmaceutical company, has received $5.5 million from Baxter Healthcare, a developer and marketer of medical products that save and sustain the lives of people with hemophilia, immune disorders, cancer, infectious diseases, kidney disease, trauma and other chronic and acute medical conditions.
Subscribe to our email newsletter
The transaction represents the final prepaid product-based payment due under the terms of its Hylenex licensing agreement, which provides Baxter with exclusive distribution rights. The payment has been booked as deferred revenue.